Dix TA - Search Results

1

Development of a Peptide-derived orally-active kappa-opioid receptor agonist targeting peripheral pain.

Hughes FM Jr, Shaner BE, Brower JO, Woods RJ, Dix TA. Hughes FM Jr, et al. Among authors: dix ta. Open Med Chem J. 2013 Nov 4;7:16-22. doi: 10.2174/1874104501307010016. eCollection 2013. Open Med Chem J. 2013. PMID: 24222801 Free PMC article.

2

Identification and functional characterization of a stable, centrally active derivative of the neurotensin (8-13) fragment as a potential first-in-class analgesic.

Hughes FM Jr, Shaner BE, May LA, Zotian L, Brower JO, Woods RJ, Cash M, Morrow D, Massa F, Mazella J, Dix TA. Hughes FM Jr, et al. Among authors: dix ta. J Med Chem. 2010 Jun 24;53(12):4623-32. doi: 10.1021/jm100092s. J Med Chem. 2010. PMID: 20481538 Free PMC article.

3

Targeting Peripheral Kappa Opioid Receptors for the Treatment of Chronic Pain: Review Article.

Beck TC, Dix TA, Reichel CM. Beck TC, et al. Among authors: dix ta. Adv Nanomed Nanotechnol Res. 2019 Jun;1(1):16-19. Epub 2018 Oct 16. Adv Nanomed Nanotechnol Res. 2019. PMID: 35494408 Free PMC article.

4

Non-addictive orally-active kappa opioid agonists for the treatment of peripheral pain in rats.

Beck TC, Reichel CM, Helke KL, Bhadsavle SS, Dix TA. Beck TC, et al. Among authors: dix ta. Eur J Pharmacol. 2019 Aug 5;856:172396. doi: 10.1016/j.ejphar.2019.05.025. Epub 2019 May 16. Eur J Pharmacol. 2019. PMID: 31103632 Free PMC article.

5

Targeting peripheral ϰ-opioid receptors for the non-addictive treatment of pain.

Beck TC, Dix TA. Beck TC, et al. Among authors: dix ta. Future Drug Discov. 2019 Oct;1(2):FDD17. doi: 10.4155/fdd-2019-0022. Epub 2019 Sep 2. Future Drug Discov. 2019. PMID: 31742251 Free PMC article.

6

Diuretic Activity of a Novel Peripherally-Restricted Orally-Active Kappa Opioid Receptor Agonist.

Beck TC, Hapstack MA, Ghatnekar GS, Dix TA. Beck TC, et al. Among authors: dix ta. Med Sci (Basel). 2019 Aug 31;7(9):93. doi: 10.3390/medsci7090093. Med Sci (Basel). 2019. PMID: 31480425 Free PMC article.

7

Comparison of N-terminal modifications on neurotensin(8-13) analogues correlates peptide stability but not binding affinity with in vivo efficacy.

Orwig KS, Lassetter MR, Hadden MK, Dix TA. Orwig KS, et al. Among authors: dix ta. J Med Chem. 2009 Apr 9;52(7):1803-13. doi: 10.1021/jm801072v. J Med Chem. 2009. PMID: 19290594

8

In vitro analysis of stable, receptor-selective neurotensin[8-13] analogues.

Kokko KP, Hadden MK, Orwig KS, Mazella J, Dix TA. Kokko KP, et al. Among authors: dix ta. J Med Chem. 2003 Sep 11;46(19):4141-8. doi: 10.1021/jm0300633. J Med Chem. 2003. PMID: 12954066

9

Synthesis and human neurotensin receptor binding activities of neurotensin(8-13) analogues containing position 8 alpha-azido-N-alkylated derivatives of ornithine, lysine, and homolysine.

Lundquist JT 4th, Dix TA. Lundquist JT 4th, et al. Among authors: dix ta. J Med Chem. 1999 Nov 18;42(23):4914-8. doi: 10.1021/jm9903444. J Med Chem. 1999. PMID: 10579853

10

Therapeutic Potential of Kappa Opioid Agonists.

Beck TC, Hapstack MA, Beck KR, Dix TA. Beck TC, et al. Among authors: dix ta. Pharmaceuticals (Basel). 2019 Jun 20;12(2):95. doi: 10.3390/ph12020095. Pharmaceuticals (Basel). 2019. PMID: 31226764 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

58 results

Search Page

Filters